The application is seeking approval for an expanded age indication for Gardasil 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine HPV types covered by the vaccine.
Five of the HPV types in Gardasil 9 are the most common cervical cancer-causing types worldwide. Seven HPV types in the vaccine cause 90% of cervical cancer cases, 80% of high-grade cervical lesions, and 50% of low-grade cervical lesions.
In addition, these seven HPV types cause 90% of HPV-related vulvar cancers, 85% of HPV-related vaginal cancers, and 90% of HPV-related anal cancers. Two of the other HPV types in the vaccine cause approximately 90% of genital warts cases.
Merck provides healthcare solutions worldwide through four segments: pharmaceutical, animal health, healthcare services, and alliances.
The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma